PrimeRFP SCOUT · Federal Contract Recompete Brief

W911SR22F0073DS process characterization — Ology Bioservices, Inc

Ology Bioservices, Inc holds $17.4M across 7 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 2 related awards under parent W911SR22D0009. Recompete timing centers on the Jan 5, 2028 PoP end — agencies typically plan 12–18 months ahead.

W6qk Acc-Apg
Awarding office
Ology Bioservices, Inc
Recipient
Jan 5, 2028
PoP end
$4.5M
Obligated
$10.8M
Potential
541715
NAICS
AN42
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Ology Bioservices, Inc — $90

Contract facts

Federal
Contract numberW911SR22F0073
Also listed asW911SR-22-F-0073
Also listed asW911SR22D0009-W911SR22F0073
AgencyW6qk Acc-Apg
Awarding officeW6qk Acc-Apg
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentOlogy Bioservices, Inc
CAGE3GQS9
UEIGC2RFAZK8G64
NAICS541715
PSCAN42
Parent IDIQ / IDVW911SR22D0009
Place of performanceALACHUA FL
Pricing typeCost Plus Fixed Fee
Extent competedNot Available For Competition
Related solicitationW911SR22R0040
PoP startJun 16, 2022
PoP end (current)Jan 5, 2028
Obligated$4.5M
Current value$10.8M
Potential value$10.8M

DS PROCESS CHARACTERIZATION is a federal award for W6qk Acc-Apg held by Ology Bioservices, Inc. Estimated value $10.8M ($4.5M obligated). Current period of performance ends Jan 5, 2028. Place of performance: ALACHUA FL. Related solicitation W911SR22R0040.

Recompete timing

Public
Expiring in 503 days

Current PoP ends Jan 5, 2028 (503 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 5, 2026.

Incumbent footprint

Public record

Ology Bioservices, Inc$17.4M obligated across 7 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($17.4M) · all agencies
Department of Defense (DOD)$11.6M · 67%Department of Health and Human Services (HHS)$5.8M · 33%

Related awards

Same parent · incumbent
W911SR23F0057
DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEV…
$67.6M
Jan 5, 2028
W911SR22F0014
CLINICAL DEVELOPMENT PHASE 2 STUDY
$107.9M
Feb 29, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract W911SR22F0073?

W911SR22F0073 (DS process characterization) is a W6qk Acc-Apg award with a potential value of $10.8M, currently held by Ology Bioservices, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W911SR-22-F-0073?

W911SR-22-F-0073 is the dashed form of PIID W911SR22F0073 (DS process characterization), held by Ology Bioservices, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W911SR22F0073?

W6qk Acc-Apg awarded W911SR22F0073 to Ology Bioservices, Inc (potential $10.8M).

Who is the incumbent on W911SR22F0073?

Ology Bioservices, Inc is the incumbent with $17.4M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Jan 5, 2028.

When does Ology Bioservices, Inc’s W911SR22F0073 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 5, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W911SR22F0073